News & Updates
Filter by Specialty:
New chemo-free triplet regimen shows promise for endometrial cancer
A triplet regimen combining the PARP inhibitor olaparib with metronomic cyclophosphamide and metformin showed favourable signals for heavily pretreated women with advanced endometrial carcinoma, the phase I/II ENDOLA study suggests.
New chemo-free triplet regimen shows promise for endometrial cancer
09 May 2022
Inconsistent PCOS diagnosis, management seen in SG clinicians
A recent study assessing the diagnostic and management processes of polycystic ovary syndrome (PCOS) adopted by clinicians from different specialties in Singapore has found certain variations, which warrant the need for standardized workplace protocols and patient education resources.
Inconsistent PCOS diagnosis, management seen in SG clinicians
06 May 2022
Open surgery a better option than minimally invasive hysterectomy in early cervical cancer?
Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.
Open surgery a better option than minimally invasive hysterectomy in early cervical cancer?
05 May 2022
New HF guideline: Quad therapy, HFmrEF, and more
Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.
New HF guideline: Quad therapy, HFmrEF, and more
04 May 2022
Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer
In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.
